We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 2.13% | 12.00 | 11.50 | 12.50 | 12.00 | 11.25 | 11.75 | 1,308,627 | 13:22:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -1.44 | 31.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
13/10/2022 10:28 | I hope you are right that Abbot throw in a bid. You can then tell everyone how right you were and that everyone else was a bed wetter for even questioning what you had been banging on about. I for one will "congratulate" you whilst I am counting the money that I have made from my investment. | vitec | |
13/10/2022 10:25 | Your sick in the head ....U really are ...U don't hold ... and spend all day on here ......Why ? ABBOT throwing a bid tomorrow !!! | amaretto1 | |
13/10/2022 10:25 | Mug punters getting drawn in while Amaretto and the gang sell in the background. | 1liam | |
13/10/2022 10:23 | Thank you - I too hold a big stake, but enough is enough. This is a long running sage of poor perfromance from AN, in cahoots with aboard that frankly has not asked difficult querstions, not held executive to account, and clearly couldnt care less about teh COmpany, given their s/holdings. | fevertreeman | |
13/10/2022 10:22 | FWIW, I worked for a man that Newland reflects. Brilliant at what he did, made a lot of money, was unable and unwilling to give up control. Finally did a management buyout but still wanted to control the company and its direction. Those that question Newland's ability have that right. No man or woman has all of the attributes to run a well oiled machine. The team ultimately are the assets within the company and drive the vision of the CEO and the BOD forward. A company run like a personal ffiefdom ultimately goes in no direction and reflects the wants and needs of the CEO. I do not know Newland but as I have stated before he will either rise to the challenge of commercialising what IP he has or someone else will take it away and do it themselves. Either way my view is liquid biopsy is the way forward. If you think about it the public once they understand the ability of a liquid biopsy will demand it over having to have a painful biopsy that cannot deliver the accuracy of a non liquid one. | vitec | |
13/10/2022 10:21 | Share price is back to levels of 2012, despite the technical progress, and despite having had 10 years of zero interest rate environment where other long duration businesses have thrived. Ultimately the sorry trajectory of the share price speaks volume about a management team (ie Newland) that the market just does not trust to create a commercially robust business around parsortix. I weish it were not so, but the Company should have listed on Nasdaq years ago ; should have bulked up its NEDs with credible board memebers; and Newland should have stepped aside for an experienced CEO. As it is 10 years of development and we as s/holders have absolutely nothing to show for the endeavours. And if it aint the product (which workd) then it has to be management. The brief moonshot post FDA approval is indicative, as the market quickly cam back to earth as realsiation dawned that AN is stillca lling the shots & so the odds of profitable delivery are very slim, and based on previous track record years away. It is so frustrating to see. | fevertreeman | |
13/10/2022 10:13 | amaretto, you attack anyone that has a different opinion and shows any dissent. These boards are for debate. Explain to me why a company with a gold standard FDA approval is significantly down from its £1.60 share price that was achieved on the day of the approval. Also why we are significantly down from the 80p raise. Why do the directors hold so little skin in the game. All of these are valid questions raised by investors and should not be shot down as if the questioner is illiterate and should not have the temerity to post such "absurd" questions. I am long and I have a significant number of shares and I am well down on my investment. Sometimes listening to people that question the validity of what is going on is a good thing and due respect should be shown to their opinion even if I disagree. | vitec | |
13/10/2022 10:02 | You speak plainly and have put your finger on the issue here - a lack of management credibility & depth, that extends through the operational team and right through to a Board of Directors with de minimis alignment with s/holders. Newland I'm afraid cannot continue like this; after 10 years plus s/holders deserve better. The NEDs are abject, and no one seems that bothered including Newland. Everyone thinks that the move will come from US medtech, but I think that given the calamitous fall since July, that private equity is teh more obvious contender. | fevertreeman | |
13/10/2022 09:55 | Wtf is the Board there for if not to support the Company. This Company gets the first FDA approval for liquid biopsy & is now close to 40 pc below the equity raise, and not a single bloody director is backing the Company with any show of support. Chairman should be forced to resign along with the useless showere of NEDs. Here are their s/holding from annual report: Coulds anyone excplain why Groen who is on the Audit, Rem & Nominations C'tee doesnt own a single bloody share? Can any one explain why Howlett's economic interest is a mere £5,000? Absolutely shameful & shocking! The Board is not fit for purpose and the institutions should force them out. 2021 2020 I F Griffiths 1,203,832 703,832 J Groen – – B Howlett 10,000 10,000 A D W Newland 7,054,686 7,054,686 G R Selvey 50,000 50,000 | fevertreeman | |
13/10/2022 09:51 | That's my point. Newland opening his mouth and stating he does not want short term investors but people in for the long haul has brought the share price partially to where it sits today. Many CEO's that run these type of companies are excellent with the science not so good at running a commercial enterprise. Large Pharma's have the technical know how and the financial muscle. This disconnect between the share price and the potential will not last forever. | vitec | |
13/10/2022 09:47 | nice top up, Waterloo. | goyathlay | |
13/10/2022 09:43 | Agreed Vitec, in my view what AGL need are partners who can lighten the load of the roll out, ideally such partners would take an equity investment into AGL to extend the cash runway / remove the need for future placings. It's possible to achieve and the ingredients are there from a fundamental / technical point of view (or they wouldn't have received FDA approval), however you need a world class management team to locate & execute the deals... time will tell whether AN & co have what it takes, however I wouldn't say the signs are positive at present. | 74tom | |
13/10/2022 09:42 | I remember when I was last in here a couple of years ago it was painful. Seemed like drops everyday. So much so that I stopped checking on it😂. Then one afternoon I randomly checked and it was up 70%. We know that happens a lot here. It's sleepy until it goes boom, and we all know that can happen at almost any moment. | stevelauren23 | |
13/10/2022 09:40 | That 9.24 trade knows something | amaretto1 | |
13/10/2022 09:39 | We have had that ...My guts telling me a bid incoming or something very tasty !! | amaretto1 | |
13/10/2022 09:37 | So capitulation? | gspanner | |
13/10/2022 09:36 | Won't sell u them ..All platforms NT | amaretto1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions